Telix Pharmaceuticals Ltd

TLX Nasdaq SEC CIK 2007191
Follow Telix Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 USD · IFRS
EPS, diluted -

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income4 fiscal years
  • Revenue
  • Net income
−$250M$0$250M$500M$750M$1BFY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$803.8M−$7.1M
FY24$516.6M$33.7M
FY23$333M$4.2M
FY22--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−20%0%20%40%60%80%FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2553.1%3.7%−0.9%
FY2465.1%10.7%6.5%
FY2362.9%3.3%1.3%
FY22---
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0$20MFY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$43M
FY24$18.4M
FY23$8M
FY22-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Telix Pharmaceuticals
  • Healthcare median
−100%−75%−50%−25%0%25%FY22FY23FY24FY25
Show the numbers
YearTelix PharmaceuticalsHealthcare median
FY25−0.9%−30.6%
FY246.5%−47%
FY231.3%−58%
FY22-−80.4%